CelLBxHealth plc (ANPCF)

Market Cap	16.28M -72.1%
Revenue (ttm)	3.60M +29.6%
Net Income	-21.62M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,000
Average Volume	14,090
Open	0.0147
Previous Close	0.0197
Day's Range	0.0147 - 0.0168
52-Week Range	0.0147 - 0.1061
Beta	0.23
RSI	33.89
Earnings Date	Jun 1, 2026

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 119
• Stock Exchange: OTCMKTS
• Ticker Symbol: ANPCF

Financial Performance

In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.

Financial numbers in GBP